Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7696 to 7710 of 8905 results

  1. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    We have moved Medical technologies guidance 33 to become HealthTech guidance 433. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. SecurAcath for securing percutaneous catheters (MTG34)

    We have moved Medical technologies guidance 34 to become HealthTech guidance 440. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Memokath-051 stent for ureteric obstruction (MTG35)

    This guidance has been updated and replaced by NICE healthtech guidance 651.

    Withdrawn guidance

  4. Peristeen Plus transanal irrigation system for managing bowel dysfunction (MTG36)

    We have moved Medical technologies guidance 36 to become HealthTech guidance 462. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Thopaz+ portable digital system for managing chest drains (MTG37)

    We have moved Medical technologies guidance 37 to become HealthTech guidance 465. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)

    We have moved Medical technologies guidance 38 to become HealthTech guidance 486. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued

  8. Diabetic foot ulcers - new treatments [ID381]

    Discontinued Reference number: GID-TAG371

    Technology appraisal guidance
    Discontinued

  9. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

    We have moved Diagnostics guidance 11 to become HealthTech guidance 320. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  11. The EOS 2D/3D imaging system (DG1)

    We have moved Diagnostics guidance 1 to become HealthTech guidance 274. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)

    This guidance has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn guidance

  13. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    We have moved Diagnostics guidance 14 to become HealthTech guidance 353. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)

    This guidance has been updated and replaced by NICE HealthTech guidance 552.

    Withdrawn guidance

  15. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    We have moved Diagnostics guidance 16 to become HealthTech guidance 360. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance